New Aspects About The Implantation Of 45 Trifocal Supplementary Intraocular Lenses In Eyes With Monofocal Primary Iols
Published 2022
- 40th Congress of the ESCRS
Reference: FPT04.08
| Type: Free paper
| DOI:
10.82333/rn68-5m98
Authors:
Carlos Palomino Bautista* 1
, Alfredo Castillo 1
, David Carmona 1
, Marta Romero 1
, Ruben Sanchez Jean 2
1Hospital Universitario Quironsalud Madrid,Pozuelo de Alarcón,Spain, 2Hospital Clínico San Carlos,Madrid,Spain
Purpose
To assessing the efficacy of the AddOn lens in patients with monofocal intraocular lenses implanted in a capsular bag
Setting
Hospital Universitario Quironsalud Madrid
Methods
The patients had no ocular pathology, no amblyopia, and all were pseudo-phakic with monofocal implants with no tilts or offsets. They were multifocused with AddOn Medicontur (trifocal) on 45 eyes, 20 bilateral and 5 monolateral implants were implanted. Age: 70.2 ± 7.08 (65, 81). They were followed up at 6 months: far, intermediate and near VA, specular endothelial micrography, angle control, defocus curve and defocus tolerance (DOF 90%). Monolateral patients had monofocals implanted and we multifocalised with AddOn. They had a diffractive lens implanted (trifocal) in their contralateral eye.
Results
At 6 months the refractive results were EE = - 0.02 ± 0.08 D, UCDVA: 0.01 ± 0.08 LogMAR, UCIVA :0.20 ± 0.12 LogMAR and UCNVA: 0.12 ± 0.06 LogMAR. The subjective DOF (90%): 0.49 ± 0.09 (0.30, 0.57) D and the DOF (90%) with itrace 0.300 ± 0.07 (0.21, 0.45). 100% of the patients showed satisfaction according to their own questionnaire.
Conclusions
Independence from glasses was achieved at all distances after the AddOn implantation. All multifocused patients were satisfied with the AddOn implant. Taking into account the limitation of the sample (n = 45), we conclude that AddOn progressive is a good and safe option for multifocalising pseudo-phakic patients with monofocal lenses.